The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Doused in Denmark

Doused in Denmark

August 1, 2009 • By David S. Pisetsky, MD, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

A second message I gained from EULAR concerns the potential for innovation in treatment. I would guess that the EULAR congress set a record in the Guinness Book for the number of new targets for immunological intervention presented. I predict that this record will be short-lived and easily broken in Philadelphia. Given the plethora of new targets and the variety of large and small molecules to block their activity, industry and its partners in academia must develop a strategy to select a chosen few agents to move through the pipeline and make sure that optimal treatment reflects the efficacy of agents rather than tradition or the date of regulatory approval. Certainly, it would be a great misfortune if the development of truly breakthrough products stopped because the marketplace look too crowded.

You Might Also Like
  • Experiencing EULAR: An ARHP Perspective
  • Medical Renaissance
  • An American in Paris
Explore This Issue
August 2009
Also By This Author
  • EULAR Magic

The news from EULAR was not all hygge (a Danish word for their cozy, familial, and tranquil ways). I have always looked at Europe as a place of growth for academic rheumatology as the economy of the continent revived and expanded and the countries of the old Eastern Bloc developed full-fledged market systems. Not surprisingly, Europe is caught in the same economic mess as the United States, and rheumatology is increasingly jeopardized as hospitals cut costs. Our side of the Atlantic also has its share of woes, and those Americans in Copenhagen bemoaned the funding situation. While the stimulus package is great, it will fund only a few of the tens of thousands of applications that have flooded www.grants.gov.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Doused in Denmark

Victims of Our Own Success?

As discussed in this column before, the decline in academic rheumatology, while very troubling, should not be a surprise. It is a direct reflection of success. If new treatments keep the HAQ and Sharp scores down, patients will not need to go to academic medical centers for their care, and research on novel agents will falter. I was recently at a lecture where a representative from the Food and Drug Administration said that there is no longer an unmet need in the treatment of RA. Unmet needs generate the growth of academic units. Met needs do not. Both in the United States and Europe, the leaders of academic rheumatology will have to think long and hard about how to put the spotlight on the unmet needs truly present (e.g., treatment of inflammatory disease in the developing world) and recast the specialty to assure in its place in the big centers.

Pages: 1 2 3 | Single Page

Filed Under: Opinion, Rheuminations Tagged With: Annual Meeting, Disease, DMARDs, EULAR, Rheumatoid arthritis, TravelIssue: August 2009

You Might Also Like:
  • Experiencing EULAR: An ARHP Perspective
  • Medical Renaissance
  • An American in Paris
  • EULAR Magic

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)